What is Haemonetics's apheresis — SG&A?

Haemonetics (HAE) reported apheresis — SG&A of $44.26M in Q2 2026.

What does apheresis — SG&A mean?

These are the operating expenses incurred to support the Apheresis segment's sales, marketing, and general administrative functions, excluding direct production costs. It reflects the overhead required to maintain and grow the segment's market presence. Investors monitor this to assess the segment's operating leverage and cost discipline.

Haemonetics (HAE) Apheresis — SG&A

Screener

Other segment segments

MedSurg

$65.16M—

Similar metrics at other companies

LENCentral — SG&A

$148.21M-2.7%

LENEast — SG&A

$162.77M+0.4%

LENHomebuilding — SG&A

$617.5M+0.3%

LENOther — SG&A

$7.71M+91.6%

LENWest — SG&A

$191.17M-5.5%

COSTCanada — SG&A

$2.2B+11.3%

Other financials

Income statement

See full

Revenue$339.4M+5.6%

Gross profit$202.8M+5.5%

Operating income$57.5M+6.7%

Net income$33.0M-3.0%

EPS (diluted)$0.72+2.9%

Balance sheet

See full

Cash & equivalents$223.4M-23.7%

Total debt$1.2B-4.1%

Total equity$837.1M-5.1%

Total assets$2.4B-3.9%

Cash flow

See full

Operating cash flow$52.3M+201%

CapEx$7.9M+111%

Free cash flow$44.4M+226%

Valuation

See full

Market cap$3.87B+6.3%

Enterprise value$4.82B+5.4%

P/E25.7×-10.5×

P/S2.9×+0.2×

Profitability

See full

Gross margin59%+2.1pp

Operating margin19%+5.9pp

Net margin13.3%+3.8pp

FCF margin21.5%+7.5pp

Returns & leverage

See full

Return on equity19.3%+5.2pp

Debt / equity1.4×0.0×

Current ratio3.1×+1.4×

Where this comes from

Reported directly by Haemonetics in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The source filing: Haemonetics’s 10-Q, filed August 6, 2026.

Filed: Aug 6, 2026, 6:09 AM EDT
Fiscal quarter: Q1 FY2027
Calendar quarter: Q2 2026
Accession: 0000313143-26-000120

Line item	Three Months Ended / June 27, 2026	Three Months Ended / June 28, 2025
Significant segment expenses and operating performance:
Apheresis
Cost of goods sold	$84,131	$75,865
Selling, general and administrative	44,264	39,880
Research and development	6,378	6,816
Apheresis operating income	$56,545	$59,175
MedSurg
Cost of goods sold	$50,368	$50,216

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Haemonetics's apheresis — SG&A?: Haemonetics (HAE) reported apheresis — SG&A of $44.26M in Q2 2026.
What does apheresis — SG&A mean?: These are the operating expenses incurred to support the Apheresis segment's sales, marketing, and general administrative functions, excluding direct production costs. It reflects the overhead required to maintain and grow the segment's market presence. Investors monitor this to assess the segment's operating leverage and cost discipline.